Pharmacodynamics of current and emerging treatments for cervical cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
   Google Scholar
• Siegel R, Ma J, Zou Z, et al. Cancer statistics 2014. CA Cancer J Clin. 2014;64:9–29.
   Google Scholar
• National Cancer Institute. Surveillance, epidemiology and end results program. Cancer statistics. SEER stat fact sheets: cervix uteri cáncer. [cited 2019 Jul 19]. Available from: http://seer.cancer.gov/statfacts/html/cervix.html
   Google Scholar
• [cited 2019 Jul 19]. Available from: http://www.datamonitor.com/store/Product/epidemiology_ cervical_cancer_the_small_decrease_in_cervical_cancer_cases_over_the_next_decade_in_the_seven_major_markets_is_driven_by_decreasing_incidence_ rates?productid=HC00202-001
   Google Scholar
• Mohar A, Frias-Mendivil M. Epidemiology of cervical cancer. Cancer Invest. 2000;18:584–590.
   Google Scholar
• Gadducci A, Sartori E, Maggino T, et al. The clinical outcome of patients with stage Ia1 and Ia2 squamous cell carcinoma of the uterine cervix: a Cooperation Task Force (CTF) study. Eur J Gynaecol Oncol. 2003;24:513–516.
   Google Scholar
• Martin-Hirsch PL, Wood NJ. Cervical cancer. Clin Evidence (Online). 2011;2011:0818.
   Google Scholar
• Plante M. Evolution in fertility-preserving options for early-stage cervical cancer: radical trachelectomy, simple trachelectomy, neoadjuvantchemotherapy. Int J Gynecol Cancer. 2013;23:982–989.
   Google Scholar
• Maneo A, Chiari S, Bonazzi C, et al. Neoadjuvant chemotherapy and conservative surgery for stage IB1 cervical cancer. Gynecol Oncol. 2008;111:438–443.
   Google Scholar
• Schmeler KM, Frumovitz M, Ramirez PT. Conservative management of early stage cervical cancer: is there a role for less radical surgery? Gynecol Oncol. 2011;120:321–325.
   Google Scholar
• Rydzewska L, Tierney J, Vale CL, et al. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev. 2012;12:CD007406.
   Google Scholar
• Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol. 2004;22:872–880.
   Google Scholar
• Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18:1606–1613.
   Google Scholar
• Dueñas-González A, Campbell S. Global strategies for the treatment of early-stage and advanced cervical cancer. Curr Opin Obstet Gynecol. 2016;28:11–17.
   Google Scholar
• Ramirez PT, Frumovitz M, Pareja R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer. N Engl J Med. 2018;379:1895–1904.
   Google Scholar
• Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC). Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database Syst Rev. 2010;(1):CD008285.
   Google Scholar
• Rezaee M, Hunting DJ, Sanche L. New insights into the mechanism underlying the synergistic action of ionizing radiation with platinum chemotherapeutic drugs: the role of low-energy electrons. Int J Radiat Oncol Biol Phys. 2013;87:847–853.
   Google Scholar
• Dueñas-González A, Zarbá JJ, Patel F, et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol. 2011;29:1678–1685.
   Google Scholar
• Pauwels B, Korst AEC, Lardon F, et al. Combined modality therapy of gemcitabine and radiation. Oncologist. 2005;10:34–51.
   Google Scholar
• Hernández P, Olivera P, Dueñas-Gonzalez A, et al. Gemcitabine activity in cervical cancer cell lines. Cancer Chemother Pharmacol. 2001;48:488–492.
   Google Scholar
• Petrelli F, De Stefani A, Raspagliesi F, et al. Radiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: A systematic review and meta-analysis. Gynecol Oncol. 2014;134:166–171.
   Google Scholar
• Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370:734–743.
   Google Scholar
• Tomao F, Papa A, Rossi L, et al. Angiogenesis and antiangiogenic agents in cervical cancer. Onco Targets Ther. 2014;7:2237–2248.
   Google Scholar
• Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol. 2002;29(6 Suppl 16):3–9.
   Google Scholar
• Tewari KS, Sill MW, Penson RT, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017;390(10103):1654–1663.
   Google Scholar
• Frenel J-S, Le Tourneau C, O’Neil B, et al. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial. J Clin Oncol. 2017;35:4035–4041.
   Google Scholar
• FDA approved drugs for oncology. [cited 2019 Jul 19]. Available from: www.cancerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology
   Google Scholar
• Weinstein IB, Begemann M, Zhou P, et al. Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. Clin Cancer Res. 1997;3:2696–2702.
   Google Scholar
• Ojesina AI, Lichtenstein L, Freeman SS, et al. Landscape of genomic alterations in cervical carcinomas. Nature. 2014;506:371–375.
   Google Scholar
• Raedler LA. Opdivo (Nivolumab): second PD-1 inhibitor receives FDA approval for unresectable or metastatic melanoma. Am Health Drug Benefits. 2015;8:180–183.
   Google Scholar
• Daly B, Bach PB, Page RD, et al. Financial conflicts of interest among oncology clinical pathway vendors. JAMA Oncol. 2018;4:255–257.
   Google Scholar
• Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 2008;224:166–182.
   Google Scholar
• Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016;375:1767–1778.
   Google Scholar
• Kurup SP, Obeng-Adjei N, Anthony SM, et al. Regulatory T cells impede acute and long-term immunity to blood-stage malaria through CTLA-4. Nat Med. 2017;23:1220–1225.
   Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–264.
   Google Scholar
• Minion LE, Tewari KS. Cervical cancer - state of the science: from angiogenesis blockade to checkpoint inhibition. Gynecol Oncol. 2018;148:609–621.
   Google Scholar
• Mezache L, Paniccia B, Nyinawabera A, et al. Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers. Mod Pathol. 2015;28:1594–1602.
   Google Scholar
• Liu C, Lu J, Tian H, et al. Increased expression of PDL1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity. Mol Med Rep. 2017;15:1063–1070.
   Google Scholar
• Lee SJ, Jang BC, Lee SW, et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-γ-induced upregulation of B7-H1 (CD274). FEBS Lett. 2006;580:755–762.
   Google Scholar
• Qin Y, Ekmekcioglu S, Forget MA, et al. Cervical cancer neoantigen landscape and immune activity is associated with human papillomavirus master regulators. Front Immunol. 2017;8:689.
   Google Scholar
• Yang W, Lu YP, Yang YZ, et al. Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status. J Obstet Gynaecol Res. 2017;43:1602–1612.
   Google Scholar
• Heeren AM, Punt S, Bleeker MC, et al. Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. Mod Pathol. 2016;29:753–763.
   Google Scholar
• Reddy OL, Shintaku PI, Moatamed NA. Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas. Diagn Pathol. 2017;12:45.
   Google Scholar
• Feng YC, Ji WL, Yue N, et al. The relationship between the PD-1/PD-L1 pathway and DNA mismatch repair in cervical cancer and its clinical significance. Cancer Manag Res. 2018;10:105–113.
   Google Scholar
• Dijkstra KK, Voabil P, Schumacher TN, et al. Genomics- and transcriptomics-based patient selection for cancer treatment with immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2:1490–1495.
   Google Scholar
• Schefter T, Winter K, Kwon JS, et al. RTOG:0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma. Int J Radiat Oncol Biol Phys. 2014;88:101–105.
   Google Scholar
• DiSilvestro PA, Ali S, Craighead PS, et al. Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB IIIA and IVA cervical carcinoma limited to the pelvis: a gynecologic oncology group study. J Clin Oncol. 2014;32:458–464.
   Google Scholar
• Kunos CA, Radivoyevitch T, Pink J, et al. Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers. Radiat Res. 2010;174:574–581.
   Google Scholar
• Plamthottam S, Sun D, Van Valkenburgh J, et al. Activity and electrochemical properties: iron complexes of the anticancer drug triapine and its analogs. J Biol Inorg Chem. 2019 Jun 27. DOI:10.1007/s00775-019-01675-0. [ Epub ahead of print].
   Google Scholar
• Kunos CA, Waggoner S, von Gruenigen V, et al. Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer. Clin Cancer Res. 2010;16:1298–1306.
   Google Scholar
• Kunos CA, Radivoyevitch T, Waggoner S, et al. Radiochemotherapy plus 3-aminopyridine-2carboxaldehyde thiosemicarbazone (3-AP, NSC # 663249) in advanced stage cervical and vaginal cancers. Gynecol Oncol. 2013;130:75–80.
   Google Scholar
• Gantt S, Casper C, Ambinder RF. Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention. Curr Opin Oncol. 2013;25:495–502.
   Google Scholar
• Wilson JM, Fokas E, Dutton SJ, et al. ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer. Radiother Oncol. 2016;119:306–311.
   Google Scholar
• Xiang T, Du L, Pham P, et al. Nelfinavir, an HIV protease inhibitor, induces apoptosis and cell cycle arrest in human cervical cancer cells via the ROS-dependent mitochondrial pathway. Cancer Lett. 2015;364:79–88.
   Google Scholar
• Hampson L, Kitchener HC, Hampson IN. Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro. Antivir Ther. 2006;11:813–825.
   Google Scholar
• Wallecha A, French C, Petit R, et al. Lm-LLO–based immunotherapies and HPV-associated disease. J Oncol. 2012;2012:542851.
   Google Scholar
• Basu P, Mehta A, Jain M, et al. A randomized phase 2 study of ADXS11-001 Listeria monocytogenes-Listeriolysin o immunotherapy with or without cisplatin in treatment of advanced cervical cancer. Int J Gynecol Cancer. 2018;28:764–772.
   Google Scholar
• Tan S, Liu K, Chai Y, et al. Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab. Protein Cell. 2018;9:135–139.
   Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. PACIFIC investigators. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377:1919–1929.
   Google Scholar
• Syed YY. Durvalumab: first global approval. Drugs. 2017;77:1369–1376.
   Google Scholar
• Yunokawa M, Katsumata N, Yamamoto H, et al. A pilot feasibility study for cisplatin plus S-1 for the treatment for advanced or recurrent cervical cancer. Cancer Chemother Pharmacol. 2013;71:1369–1374.
   Google Scholar
• Katsumata N, Hirai Y, Kamiura S, et al. Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer. Ann Oncol. 2011;22:1353–1357.
   Google Scholar
• Aoki Y, Ochiai K, Lim S, et al. Phase III study of cisplatin with or without S-1 in patients with stage IVB, recurrent, or persistentcervical cancer. Br J Cancer. 2018;119:530–537.
   Google Scholar
• Moore KN, Dresher C, Liu J, et al. Phase 1/2 open-label, multiple ascending dose trial of AGEN2034, an anti-PD-1 monoclonal antibody, in advanced solid malignancies: results of dose escalation. J Clin Oncol. 2018;36(suppl 15):3086.
   Google Scholar
• Gombos RB, Gonzalez A, Manrique M, et al. Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody. PLoS One. 2018;13:e0191926.
   Google Scholar
• Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11:120.
   Google Scholar
• Xie C, Wan X, Quan H, et al. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci. 2018;109:1207–1219.
   Google Scholar
• Breij EC, de Goeij BE, Verploegen S, et al. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. Cancer Res. 2014;74:1214–1226.
   Google Scholar
• de Bono JS, Concin N, Hong DS, et al. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20:383–393.
   Google Scholar
• Shah NJ, Kelly WJ, Liu SV, et al. Product review on the Anti-PD-L1 antibody atezolizumab. Hum Vaccin Immunother. 2018;14:269–276.
   Google Scholar
• Liao S, Xiao S, Zhu G, et al. CD38 is highly expressed and affects the PI3K/Akt signaling pathway in cervical cancer. Oncol Rep. 2014;32:2703–2709.
   Google Scholar
• van de Donk NW, Janmaat ML, Mutis T, et al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol Rev. 2016;270:95–112.
   Google Scholar
• Yu X, Huang X, Chen X, et al. Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy. MAbs. 2019;26:1–10.
   Google Scholar
• Ghosh S, Sharma G, Travers J, et al. TSR-033, a novel therapeutic antibody targeting lag-3, enhances t-cell function and the activity of pd-1 blockade in vitro and in vivo. Mol Cancer Ther. 2019;18:632–641.
   Google Scholar
• McKeage K. Daratumumab: first global approval. Drugs. 2016;76:275–281.
   Google Scholar
• Markham A, Duggan S. Cemiplimab: first global approval. Drugs. 2018;78:1841–1846.
   Google Scholar
• Jiang M, Milner J. Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene. 2002;21:6041–6048.
   Google Scholar
• Sima N, Wang S, Wang W, et al. Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescencein SiHa cervical carcinoma cells. Gynecol Oncol. 2007;106:299–304.
   Google Scholar
• Bousarghin L, Touze A, Gaud G, et al. Inhibition of cervical cancer cell growth by human papillomavirus virus-like particles packaged with human papillomavirus oncoprotein short hairpin RNAs. Mol Cancer Ther. 2009;8:357–365.
   Google Scholar
• Gu W, Putral L, Hengst K, et al. Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 andE7 oncogenes. Cancer Gene Ther. 2006;13:1023–1032.
   Google Scholar
• Putral LN, Bywater MJ, Gu W, et al. RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin. Mol Pharmacol. 2005;68:1311–1319.
   Google Scholar
• Lea JS, Sunaga N, Sato M, et al. Silencing of HPV 18 oncoproteins with RNA interference causes growth inhibition of cervical cancer cells. Reprod Sci. 2007;14:20–28.
   Google Scholar
• Zhou Y, Zhang C, Liang W. Development of RNAi technology for targeted therapy - A track of siRNA based agents to RNAi therapeutics. J Control Release. 2014;193:270–281.
   Google Scholar
• No authors listed. RNA-based therapies have their day. EBioMedicine. 2018;34:1.
   Google Scholar
• Fradet-Turcotte A, Archambault J. Recent advances in the search for antiviral agents against human papillomaviruses. Antivir Ther. 2007;12:431–451.
   Google Scholar
• Deutsch E, Haie-Meder C, Bayar MA, et al. Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients. Oncotarget. 2016;7:25549–25557.
   Google Scholar
• Massarelli E, William W, Johnson F, et al. Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: a phase 2 clinical trial. JAMA Oncol. 2019;5:67–73.
   Google Scholar
• Welters MJ, van der Sluis TC, van Meir H, et al. Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses. Sci Transl Med. 2016;8(334):334ra52.
   Google Scholar
• Pukac L, Kanakaraj P, Humphreys R, et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer. 2005;92:1430–1441.
   Google Scholar
• Trarbach T, Moehler M, Heinemann V, et al. Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1(TRAIL-R1) in patients with refractory colorectal cancer. Br J Cancer. 2010;102:506–512.
   Google Scholar
• Stevanović S, Draper LM, Langhan MM, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol. 2015;33:1543–1550.
   Google Scholar
• Stevanović S, Helman SR, Wunderlich JR, et al. A phase ii study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers. Clin Cancer Res. 2019;25:1486–1493.
   Google Scholar
• Kim TJ, Jin HT, Hur SY, et al. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients. Nat Commun. 2014;5:5317.
   Google Scholar
• Bonomi P, Blessing JA, Stehman FB, et al. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 1985;3:1079–1085.
   Google Scholar
• Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a gynecologic oncology group study. J Clin Oncol. 2009;27:4649–4655.
   Google Scholar
• Rose PG, Degeest K, McMeekin S, et al. A phase I study of gemcitabine followed by cisplatin concurrent with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study. Gynecol Oncol. 2007;107:274–279.
   Google Scholar
• Swisher EM, Swensen RE, Greer B, et al.; Puget Sound Oncology Consortium. Weekly gemcitabine and cisplatin in combination with pelvic radiation in the primary therapy of cervical cancer: a phase I trial of the Puget sound oncology consortium. Gynecol Oncol. 2006;101:429–435.
   Google Scholar
• Mell LK, Saenz CC, Yashar CM, et al. Phase 1 trial of bone marrow sparing intensity modulated radiation therapy with concurrent cisplatin and gemcitabine in stage ib-iva cervical cancer. Int J Radiother Oncol Biol Phys. 2016;96(2S). DOI:10.1016/j.ijrobp.2016.06.048.
   Google Scholar
• Long HJ 3rd, Bundy BN, Grendys EC Jr, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a gynecologic oncology group study. J Clin Oncol. 2005;23:4626–4633.
   Google Scholar